Where is GeneDx located?

GeneDx is headquartered in Gaithersburg, United States.

How many employees does GeneDx have?

As of Sep 30, 2026, the latest employee count at GeneDx is 1288.

How much is GeneDx worth?

The last known valuation of GeneDx was $***** as of Jan 18, 2022.

What is the annual revenue of GeneDx?

Annual revenue of GeneDx is between $100M and $500M as on Dec 31, 2025

Where does GeneDx rank among its competitors?

GeneDx ranks 4th amongst 123 active competitors, of which 24 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Turbine, which secured $25M in Feb, 2026.

Who are the top competitors of GeneDx?

GeneDx's top competitors include Natera, LifeCell and Lantern Pharma. Among them, Turbine secured the most recent funding round in February, 2026.

GeneDx - 2026 Company Profile, Team, Funding, Competitors & Financials

Q: Is GeneDx an acquired company?

GeneDx got acquired by Sema4 on Jan 18, 2022.

GeneDx is an acquired company based in Gaithersburg (United States), founded in 2000 by Sherri Bale and John Compton. It operates as a Provider of genetic testing for inherited disorders. , with last known valuation of $*****. The company has 123 active competitors, including 24 funded and 18 that have exited. Its top competitors include companies like Natera, LifeCell and Lantern Pharma.

Company Details

Provider of genetic testing for inherited disorders. The company has CLIA certified labs that carry out genetic tests covering a range of medical specialties including cardiology, endocrinology, metabolic disorders, developmental disorders, hematology, immunology, oncology (hereditary cancer syndromes), among others. The company offers whole-exome sequencing with or without mitochondrial DNA sequencing, with or without reporting of incidental findings in the clinical reports.

Website: www.genedx.com
Social
Email ID: *****@genedx.com

Key Metrics

Founded Year

2000

Location

Gaithersburg, United States

Stage

Acquired

Last Known Valuation

$***** as on Jan 18, 2022

Investors

Oak HC/FT & 2 more

Ranked

4^th among 123 active competitors

Annual Revenue

$100M - $500M as on Dec 31, 2025

Employee Count

1,288 as on Sep 30, 2026

Investment & Acquisitions

Fabric Genomics

Similar Companies

Natera & 160 more

Exit Details

Acquired by Sema4 (Jan 18, 2022)

View GeneDx's full profile

GeneDx is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
GENEDX, LLC CIN: 6554062 , United States, Active	Aug 01, 2022	-	-	-
GENEDX HOLDINGS CORP. CIN: 1818331 , United States, Active	Jul 09, 2020	$100M - $500M (As on Dec 31, 2025)	1200 (As on Dec 31, 2021)	-
GeneDx, Inc. CIN: 205446298 , United States, Active	Dec 31, 1999	-	439 (As on Dec 31, 2016)	-

GeneDx got acquired by Sema4 on Jan 18, 2022 at an acquisition amount of $*****.

Click here to take a look at GeneDx's acquisition in detail

GeneDx is a funded company. GeneDx has 3 institutional investors.

View details of GeneDx's funding rounds and investors

The founders of GeneDx are Sherri Bale and John Compton.

Here are the details of GeneDx's key team members:

Sherri Bale: Co-Founder & Managing Director of GeneDx.
Contact Info: 1 email address
John Compton: Co-Founder & Consultant of GeneDx.
Andrea wesissmann: CEO of GeneDx.

View details of GeneDx's Founder profiles and Board Members

GeneDx's employee count trend

GeneDx has 1,288 employees as of Sep 26. Here is GeneDx's employee count trend over the years:

Uncover GeneDx's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of GeneDx include Natera, LifeCell and Lantern Pharma. Here is the list of Top 10 competitors of GeneDx, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Natera 2004, Redwood City (United States), Public	Developer of cell-free DNA testing for oncology, women’s health, and organ health	$152M	Harmony Partners, Bain Capital Life Sciences ... & 18 others	77/100
2nd	LifeCell 2004, Chennai (India), Series B	A stem cell banking company specializing in cord blood and tissue preservation	$61.2M	Orbimed, Helion Venture Partners & 74 others	74/100
3rd	Lantern Pharma 2013, Dallas (United States), Public	Developing drug and companion diagnostics for multi-drug resistant cancers	$7.12M	Green Park & Golf Ventures, Bios Partners ... & 3 others	62/100
4th	GeneDx 2000, Gaithersburg (United States), Acquired	Provider of genetic testing for inherited disorders	-	Oak HC/FT, S32 & 1 others	64/100
5th	Nucleus Genomics 2021, Manhattan (United States), Series A	Provider of genetic testing kits for rare variant analysis	$32M	Founders Fund, Kube VC & 27 others	62/100
6th	Turbine 2015, Budapest (Hungary), Series B	Provider of an AI based cancer therapy management software for researchers and doctors	$61.7M	Merck Global Health Innovation Fund, MassMutual Ventures ... & 19 others	58/100
7th	RareCyte 2009, Seattle (United States), Series C	Developer of technologies for the analysis of rare and single cells in the blood	$114M	Arboretum Ventures, Health Quest Capital ... & 11 others	57/100
8th	Mylab 2016, Pune (India), Seed	Developer of diagnostic kits for pathogen detection and viral load monitoring	-	Rising Sun Holdings, Zydus Life & 10 others	57/100
9th	Rgenta 2018, Cambridge (United States), Series A	Developer of RNA-based therapeutics for multiple disorders	$90M	Boehringer Ingelheim Venture Fund, AstraZeneca ... & 11 others	56/100
10th	Sema4 2017, Stamford (United States), Public	Provider of genome-based diagnostic testing solutions for reproductive health and oncology	$241M	Section 32, Oak HC/FT & 6 others	56/100